GitHub’s Octoverse 2025 report reveals a "convenience loop" where AI coding assistants drive language choice. TypeScript’s 66% surge to the #1 spot highlights a shift toward static typing, as types ...
Biological systems are notoriously tough to model, especially when it comes to figuring out the axons, neurons, blood vessels, and other structural components of gray matter, or the tissue that makes ...
WASHINGTON — Array Labs, a Silicon Valley startup developing radar-based Earth observation satellites, announced Jan. 5 it raised $20 million in a Series A round as it pushes to bring lower-cost ...
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 7 minutes ...
Marika Taylor currently receives funding from EPSRC, STFC, UK government deparments and the European Horizon programme. In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the ...
The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...
Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...
NEW YORK - September 9, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks ...
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results